Sana Sees 14-Month Insulin Production for Transplanted Islet Therapy in Single Type 1 Diabetes Patient

Seattle-based Sana Biotechnology reported that its donor-derived islet cell therapy UP421 remained undetected by the immune system and continued functioning more than a year after transplant in a patient with Type 1 diabetes. The therapy maintained stable insulin-related biomarker levels, demonstrated beta-cell survival, and showed improved insulin response and glycemic control between months 12 and 14.